AIMS: To evaluate phenotypic and genetic variables associated with a poor long-term response to inhaled corticosteroid therapy for asthma, based independently on lung function changes or asthma exacerbations. MATERIALS & METHODS: We tested 17 phenotypic variables and polymorphisms in FCER2 and CRHR1 in 311 children (aged 5-12 years) randomized to a 4-year course of inhaled corticosteroid during the Childhood Asthma Management Program (CAMP). RESULTS: Predictors of recurrent asthma exacerbations are distinct from predictors of poor lung function response. A history of prior asthma exacerbations, younger age and a higher IgE level (p < 0.05) are associated with recurrent exacerbations. By contrast, lower bronchodilator response to albuterol and the minor alleles of RS242941 in CRHR1 and T2206C in FCER2 (p < 0.05) are associated with poor lung function response. Poor lung function response does not increase the risk of exacerbations and vice versa (p = 0.72). CONCLUSION: Genetic and phenotypic predictors of a poor long-term response to inhaled corticosteroids differ markedly depending on definition of outcome (based on exacerbations vs lung function). These findings are important in comparing outcomes of clinical trials and in designing future pharmacogenetic studies.
RCT Entities:
AIMS: To evaluate phenotypic and genetic variables associated with a poor long-term response to inhaled corticosteroid therapy for asthma, based independently on lung function changes or asthma exacerbations. MATERIALS & METHODS: We tested 17 phenotypic variables and polymorphisms in FCER2 and CRHR1 in 311 children (aged 5-12 years) randomized to a 4-year course of inhaled corticosteroid during the Childhood Asthma Management Program (CAMP). RESULTS: Predictors of recurrent asthma exacerbations are distinct from predictors of poor lung function response. A history of prior asthma exacerbations, younger age and a higher IgE level (p < 0.05) are associated with recurrent exacerbations. By contrast, lower bronchodilator response to albuterol and the minor alleles of RS242941 in CRHR1 and T2206C in FCER2 (p < 0.05) are associated with poor lung function response. Poor lung function response does not increase the risk of exacerbations and vice versa (p = 0.72). CONCLUSION: Genetic and phenotypic predictors of a poor long-term response to inhaled corticosteroids differ markedly depending on definition of outcome (based on exacerbations vs lung function). These findings are important in comparing outcomes of clinical trials and in designing future pharmacogenetic studies.
Authors: J D Leuppi; C M Salome; C R Jenkins; S D Anderson; W Xuan; G B Marks; H Koskela; J D Brannan; R Freed; M Andersson; H K Chan; A J Woolcock Journal: Am J Respir Crit Care Med Date: 2001-02 Impact factor: 21.405
Authors: Stanley J Szefler; Richard J Martin; Tonya Sharp King; Homer A Boushey; Reuben M Cherniack; Vernon M Chinchilli; Timothy J Craig; Myrna Dolovich; Jeffrey M Drazen; Joanne K Fagan; John V Fahy; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Elizabeth Mauger; Stephen P Peters; Christine A Sorkness Journal: J Allergy Clin Immunol Date: 2002-03 Impact factor: 10.793
Authors: Stanley Szefler; Scott Weiss; James Tonascia; N Franklin Adkinson; Bruce Bender; Reuben Cherniack; Michele Donithan; H William Kelly; Joseph Reisman; Gail G Shapiro; Alice L Sternberg; Robert Strunk; Virginia Taggart; Mark Van Natta; Robert Wise; Margaret Wu; Robert Zeiger Journal: N Engl J Med Date: 2000-10-12 Impact factor: 91.245
Authors: E R Martin; E H Lai; J R Gilbert; A R Rogala; A J Afshari; J Riley; K L Finch; J F Stevens; K J Livak; B D Slotterbeck; S H Slifer; L L Warren; P M Conneally; D E Schmechel; I Purvis; M A Pericak-Vance; A D Roses; J M Vance Journal: Am J Hum Genet Date: 2000-06-21 Impact factor: 11.025
Authors: Kelan G Tantisira; Stephen Lake; Eric S Silverman; Lyle J Palmer; Ross Lazarus; Edwin K Silverman; Stephen B Liggett; Erwin W Gelfand; Lanny J Rosenwasser; Brent Richter; Elliot Israel; Michael Wechsler; Stacey Gabriel; David Altshuler; Eric Lander; Jeffrey Drazen; Scott T Weiss Journal: Hum Mol Genet Date: 2004-05-05 Impact factor: 6.150
Authors: Ronina A Covar; Stanley J Szefler; Robert S Zeiger; Christine A Sorkness; Mark Moss; David T Mauger; Susan J Boehmer; Robert C Strunk; Fernando D Martinez; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2008-10 Impact factor: 10.793
Authors: M Acharya; G Borland; A L Edkins; L M Maclellan; J Matheson; B W Ozanne; W Cushley Journal: Clin Exp Immunol Date: 2010-10 Impact factor: 4.330
Authors: Niloufar Farzan; Susanne J Vijverberg; Anand K Andiappan; Lambang Arianto; Vojko Berce; Natalia Blanca-López; Hans Bisgaard; Klaus Bønnelykke; Esteban G Burchard; Paloma Campo; Glorisa Canino; Bruce Carleton; Juan C Celedón; Fook Tim Chew; Wen Chin Chiang; Michelle M Cloutier; Denis Daley; Herman T Den Dekker; F Nicole Dijk; Liesbeth Duijts; Carlos Flores; Erick Forno; Daniel B Hawcutt; Natalia Hernandez-Pacheco; Johan C de Jongste; Michael Kabesch; Gerard H Koppelman; Vangelis G Manolopoulos; Erik Melén; Somnath Mukhopadhyay; Sara Nilsson; Colin N Palmer; Maria Pino-Yanes; Munir Pirmohamed; Uros Potočnik; Jan A Raaijmakers; Katja Repnik; Maximilian Schieck; Yang Yie Sio; Rosalind L Smyth; Csaba Szalai; Kelan G Tantisira; Steve Turner; Marc P van der Schee; Katia M Verhamme; Anke H Maitland-van der Zee Journal: Pharmacogenomics Date: 2017-06-22 Impact factor: 2.533
Authors: Gregory S Sawicki; Robert C Strunk; Brooke Schuemann; Robert Annett; Scott Weiss; Anne L Fuhlbrigge Journal: Ann Allergy Asthma Immunol Date: 2010-01 Impact factor: 6.347
Authors: Ann Chen Wu; Kelan Tantisira; Lingling Li; Brooke Schuemann; Scott T Weiss; Anne L Fuhlbrigge Journal: Chest Date: 2011-02-03 Impact factor: 9.410
Authors: Heather M Byers; John M Dagle; Jonathan M Klein; Kelli K Ryckman; Erin L McDonald; Jeffrey C Murray; Kristi S Borowski Journal: Pediatr Res Date: 2011-12-21 Impact factor: 3.756